.
labour�s new study is based on freedom of information data from 95 english nhs trust.
.
.in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
. copyright © the asahi shimbun company. all rights reserved. no reproduction or republication without written permission.